Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Total Non-Current Liabilities of $134.6 million for Q1 2026, up 17.76% year-on-year from $114.3 million in Q1 2025, and down 9.95% on a QoQ basis from $149.5 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 16 years of Total Non-Current Liabilities data on file, last reported at $134.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 17.76% year-over-year to $134.6 million; the trailing twelve-month figure through Mar 2026 stood at $134.6 million (up 17.76% YoY), and the FY2025 full-year result was $149.5 million, up 21.09% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $134.6 million, down from $149.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $149.5 million in Q4 2025 and bottomed at $48.3 million in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $95.3 million (2024), against an average of $94.7 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities soared 97.52%; it then gained 17.76% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $61.1 million in 2022, then grew by 29.61% to $79.3 million in 2023, then surged by 55.79% to $123.5 million in 2024, then climbed by 21.09% to $149.5 million in 2025, then dropped by 9.95% to $134.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $134.6 million (Q1 2026), $149.5 million (Q4 2025), and $131.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 134.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.63 Mn |
| Dec 31, 2025 | 149.50 Mn |
| Sep 30, 2025 | 131.20 Mn |
| Jun 30, 2025 | 115.58 Mn |
| Mar 31, 2025 | 114.33 Mn |
| Dec 31, 2024 | 123.46 Mn |
| Sep 30, 2024 | 108.28 Mn |
| Jun 30, 2024 | 95.31 Mn |
| Mar 31, 2024 | 82.66 Mn |
| Dec 31, 2023 | 79.25 Mn |
| Sep 30, 2023 | 61.09 Mn |
| Jun 30, 2023 | 55.88 Mn |
| Mar 31, 2023 | 60.18 Mn |
| Dec 31, 2022 | 61.15 Mn |
| Sep 30, 2022 | 48.32 Mn |
| Dec 31, 2021 | 30.96 Mn |
| Dec 31, 2019 | 24.75 Mn |
| Jun 30, 2019 | 14.15 Mn |
| Mar 31, 2019 | 9.90 Mn |
| Dec 31, 2018 | 9.51 Mn |
| Sep 30, 2018 | 3.47 Mn |
| Jun 30, 2018 | 3.08 Mn |
| Mar 31, 2018 | 2.73 Mn |
| Dec 31, 2017 | 4.27 Mn |
| Sep 30, 2017 | 2.74 Mn |
| Jun 30, 2017 | 1.84 Mn |
| Mar 31, 2017 | 2.08 Mn |
| Dec 31, 2016 | 2.28 Mn |
| Sep 30, 2016 | 2.22 Mn |
| Jun 30, 2016 | 2.43 Mn |
| Mar 31, 2016 | 2.85 Mn |
| Dec 31, 2015 | 4.45 Mn |
| Sep 30, 2015 | 2.52 Mn |
| Jun 30, 2015 | 5.53 Mn |
| Mar 31, 2015 | 5.86 Mn |
| Dec 31, 2014 | 8.65 Mn |
| Sep 30, 2014 | 5.95 Mn |
| Jun 30, 2014 | 2.38 Mn |
| Mar 31, 2014 | 2.45 Mn |
| Dec 31, 2013 | 2.16 Mn |
| Sep 30, 2013 | 6.56 Mn |
| Jun 30, 2013 | 2.68 Mn |
| Mar 31, 2013 | -21,265.00 |
| Dec 31, 2012 | 1.67 Mn |
| Sep 30, 2012 | -1.93 Mn |
| Jun 30, 2012 | -594,114.00 |
| Mar 31, 2012 | 2.25 Mn |
| Dec 31, 2011 | 2.48 Mn |
| Dec 31, 2010 | 298,961.00 |